We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
+$60.4M
Cap. Flow
-$61.1M
Cap. Flow %
-5.98%
Top 10 Hldgs %
49.68%
Holding
183
New
37
Increased
35
Reduced
45
Closed
53

Top Buys

Rank Stock Value
1
BCOM
B Communications Ltd
BCOM
+$95.7M
2
BIIB icon
Biogen
BIIB
+$20.4M
3
CELG
Celgene Corp
CELG
+$10.3M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$7.22M
5
ATXS
Astria Therapeutics
ATXS
+$5.62M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$18.8M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
3
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.5M
4
AMGN icon
Amgen
AMGN
+$9.61M
5
IWM icon
iShares Russell 2000 ETF
IWM
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 50.75%
2 Technology 3.95%
3 Utilities 1.35%
4 Industrials 0.96%
5 Consumer Discretionary 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTIC
101
DELISTED
Otonomy, Inc.
OTIC
$2.6M 0.25%
113,000
+43,000
+61% +$1.21M
TRVN
102
DELISTED
Trevena, Inc.
TRVN
$2.57M 0.25%
656
+29
+5% +$123K
ELLO icon
103
Ellomay Capital Ltd
ELLO
$270M
$2.52M 0.25%
246,697
+25,019
+11% +$207K
SNA icon
104
Snap-on
SNA
$21.2B
$2.44M 0.24%
15,340
– –
TBRA
105
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$2.37M 0.23%
+137,622
New +$2.01M
TTPH
106
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.35M 0.23%
2,475
-1,275
-34% -$1.04M
SMMT icon
107
Summit Therapeutics
SMMT
$10.4B
$2.28M 0.22%
205,200
+30,200
+17% +$342K
PTN
108
Palatin Technologies
PTN
$13.7M
$2.26M 0.22%
2,032
+1,200
+144% +$1.44M
WAB icon
109
Wabtec
WAB
$49.1B
$2.11M 0.21%
22,365
+865
+4% +$84.9K
ALDX icon
110
Aldeyra Therapeutics
ALDX
$92.9M
$2.06M 0.2%
265,000
+150,000
+130% +$1.29M
RCKT icon
111
Rocket Pharmaceuticals
RCKT
$340M
$1.86M 0.18%
95,000
-5,000
-5% -$111K
CHTR icon
112
Charter Communications
CHTR
$17.3B
$1.72M 0.17%
+10,065
New +$1.81M
TW
113
DELISTED
TOWERS WATSON & CO COM STK CL A (DE)
TW
$1.61M 0.16%
12,807
-25,493
-67% -$3.42M
EXEL icon
114
Exelixis
EXEL
$13.3B
$1.5M 0.15%
400,000
-100,000
-20% -$325K
APTO
115
DELISTED
Aptose Biosciences, Inc.
APTO
$1.42M 0.14%
+491
New +$1.28M
BRCM
116
DELISTED
BROADCOM CORP CL-A
BRCM
$1.28M 0.13%
24,894
-75,906
-75% -$3.69M
VFC icon
117
VF Corp
VFC
$5.63B
$1.23M 0.12%
18,691
-26,094
-58% -$1.76M
NICE icon
118
Nice
NICE
$5.79B
$1.16M 0.11%
+18,250
New +$1.15M
IMMU
119
DELISTED
Immunomedics Inc
IMMU
$995K 0.1%
245,000
-55,000
-18% -$225K
GNVC
120
DELISTED
GenVec, Inc.
GNVC
$735K 0.07%
36,033
-16,800
-32% -$410K
IPXL
121
DELISTED
Impax Laboratories, Inc.
IPXL
$689K 0.07%
15,000
-85,000
-85% -$4.03M
SPNS
122
DELISTED
Sapiens International
SPNS
$586K 0.06%
56,420
– –
TVRD
123
Tvardi Therapeutics
TVRD
$19.7M
$567K 0.06%
+1,297
New +$501K
GALT icon
124
Galectin Therapeutics
GALT
$196M
$560K 0.05%
205,000
-245,000
-54% -$739K
ZSAN
125
DELISTED
Zosano Pharma Corporation
ZSAN
$452K 0.04%
89
-175
-66% -$1.08M
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sphera Funds Management held 183 positions worth $1.02B, up 6.3% from $961M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management withdrew a net $61.1M in Q2 2015, closing 53 positions and reducing 45 holdings. Its most notable exit was Endo International plc, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in B Communications Ltd worth $6.45M.

  • Sphera Funds Management's largest Q2 2015 buy was B Communications Ltd: 5,977,000 shares worth $6.45M.
  • Sphera Funds Management added most to Biogen in Q2 2015, an estimated $20.4M increase.
  • Sphera Funds Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $13.9M.
  • Sphera Funds Management fully exited Endo International plc in Q2 2015, selling an estimated $18.8M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.02B portfolio in Q2 2015.
  • Sphera Funds Management opened 37 new positions and closed 53 in Q2 2015.
  • Sphera Funds Management's portfolio value rose 6.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.